bioRxiv · 10.64898/2026.02.04.703808
Long-term rapamycin treatment suppresses IL-17-producing gamma delta T cells and blunts neuroinflammation in aging
Abstract
Aging is the gradual accumulation of structural and functional changes in an organism over time, including immune remodeling and a progressive increase in basal inflammation, or inflammaging. The mTOR pathway is a central driver of aging-related diseases, such as cancer, chronic inflammation and neurodegeneration; pharmacological inhibition with rapamycin is associated with reduced aged-related morbidity and increased lifespan across species. Nonetheless, concerns remain about the use of rapamycin, a well-established immunosuppressant in transplant medicine, as an anti-aging intervention. Here, we evaluated the impact of prolonged low-dose dietary rapamycin on the aging immune system. Treatment did not significantly alter innate or adaptive immune cell populations, including brain resident microglia; however, it attenuated the age-associated accumulation of IL-17-producing {gamma}{delta} T cells, particularly in the peritoneal cavity. After a peripheral inflammatory LPS challenge, circulating IL-17 levels were significantly reduced and correlated with an attenuation of microglia inflammatory phenotype. These findings suggest that prolonged low-dose rapamycin exposure exerts minor systemic immune changes, while selectively limiting age-related {gamma}{delta} T cell expansion and neuroinflammation associated with systemic inflammation.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Torrent, C., Gagliardi, C., Fülle, N., Antignano, I., Bernis, M. E., Stork, M., Bano, D., Capasso, M., Keane, L.. 2026-02-06. Long-term rapamycin treatment suppresses IL-17-producing gamma delta T cells and blunts neuroinflammation in aging. https://doi.org/10.64898/2026.02.04.703808
Cite the original work for its findings. Save a collection to share your selection of sources.